New Delhi, July 31 -- Sun Pharmaceutical Industries Ltd's revenue from operations for the April-June period beat Street expectations to rise 9.4% year-on-year to Rs.13,851 crore. However, the drugmaker's net profit fell on exceptional items including settlement costs in a pricing antitrust litigation in the US and discontinuing clinical studies on one of its drugs.

The company posted a net profit of Rs.2,279 crore in Q1FY26, down 20% from a year earlier.

A healthy double-digit growth in its India business and innovative medicines pipeline boosted its revenue and Ebitda margins during the quarter. The drugmaker has been banking on both segments to drive growth in FY26.

Its adjusted net profit, excluding the exceptional items, for Q1FY26...